Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases

Carl J. Lavie, MD,* Richard V. Milani, MD,* Mandeep R. Mehra, MD,† Hector O. Ventura, MD*

New Orleans, Louisiana; and Baltimore, Maryland

Omega-3 polyunsaturated fatty acid (ω-3 PUFA) therapy continues to show great promise in primary and, particularly in secondary prevention of cardiovascular (CV) diseases. The most compelling evidence for CV benefits of ω-3 PUFA comes from 4 controlled trials of nearly 40,000 participants randomized to receive eicosapentaenoic acid (EPA) with or without docosahexaenoic acid (DHA) in studies of patients in primary prevention, after myocardial infarction, and most recently, with heart failure (HF). We discuss the evidence from retrospective epidemiologic studies and from large randomized controlled trials showing the benefits of ω-3 PUFA, specifically EPA and DHA, in primary and secondary CV prevention and provide insight into potential mechanisms of these observed benefits. The target EPA + DHA consumption should be at least 500 mg/day for individuals without underlying overt CV disease and at least 800 to 1,000 mg/day for individuals with known coronary heart disease and HF. Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA that provides maximal cardioprotection in those at risk of CV disease as well in the treatment of atherosclerotic, arrhythmic, and primary myocardial disorders.  

Fish oil is a whale of a story, that not surprisingly gets bigger with every telling. —Rogans (1)

Fish oil is obtained in the human diet by eating oily fish, such as herring, mackerel, salmon, albacore tuna, and sardines, or by consuming fish oil supplements or cod liver oil. However, fish do not naturally produce these oils, but obtain them through the ocean food chain from the marine microorganisms that are the original source of the omega-3 polyunsaturated fatty acids (ω-3 PUFA) found in fish oils. Numerous prospective and retrospective trials from many countries, including the U.S., have shown that moderate fish oil consumption decreases the risk of major cardiovascular (CV) events, such as myocardial infarction, and most recently, with heart failure (HF) (2–8). Considerable attention has been directed at the various classes of fatty acids and their impact on the prevention and treatment of CV diseases (2) (Table 1). Most of the evidence for benefits of the ω-3 PUFA has been obtained for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the long-chain fatty acids in this family. There is, however, some epidemiological support for a benefit from alpha-linolenic acid (ALA), the plant-based precursor of EPA. The American Heart Association (AHA) has currently endorsed the use of ω-3 PUFA at a dose of approximately 1 g/day of combined DHA and EPA, either in the form of fatty fish or fish oil supplements (in capsules or liquid form) in patients with documented CHD (9). The health benefits of these long-chain fatty acids are numerous and remain an active area of research (Table 2).

The purpose of this review is to summarize the current scientific data on the effects of the long chain ω-3 PUFA in the primary and secondary prevention of various CV disorders and to highlight potential directions for CV research with these agents.

Background Epidemiologic Evidence

During the past 3 decades, numerous epidemiologic and observational studies have been published on the CV benefits of ω-3 PUFA (2–5). As early as 1944, Sinclair (10) described the rarity of CHD in Greenland Eskimos, who consumed a diet high in whale, seal, and fish. More than 30 years ago, Bang and Dyberg (11–13) reported that despite a diet low in fruit, vegetables, and complex carbohydrates but...
high in saturated fat and cholesterol, serum cholesterol and triglycerides were lower in Greenland Inuit than in age-matched residents of Denmark, and the risk of MI was markedly lower in the Greenland population compared with the Danes. These initial observations raised speculation on the potential benefits of ω-3 PUFA (particularly EPA and DHA) as the protective “Eskimo factor” (14). Although a detailed review of all epidemiologic studies is beyond the scope of this article, data from Japan, Norway, Holland, and the U.S. have extended the seminal work of Bang and Dyberg (2,3,14). Recent evidence, however, has raised the concern that intrusion of Western dietary habits, including massive amounts of shortening and other saturated fats, into societies such as the Alaskan Native and Japanese may partly overwhelm the cardioprotective effects of ω-3 PUFA (14).

Trials in CHD

Harris et al. (15) have reviewed 25 trials that evaluated the risk of CHD events as a function of in vivo levels of ω-3 PUFA and showed that reduction in major CV events correlated inversely with the tissue levels of EPA, and even more so, with DHA.

Three large randomized trials have documented the effects of ω-3 PUFA in primary and especially in secondary prevention of CHD. In a randomized trial (DART [Diet and Reinfarction Trial]) (16) performed 2 decades ago in 2,033 men with recent MI, ω-3 PUFA, either in the form of oily fish or fish oil capsules, reduced 2-year all-cause mortality by 29% with the benefit almost entirely attributable to a reduction in CHD mortality. The reduction in CV events was particularly impressive in the subgroup who consumed fish oil capsules as opposed to simply increasing dietary fish consumption, likely indicating a threshold effect of ω-3 PUFA.

More recently, 2 major randomized control trials were performed. The GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico)-Prevenzione study (6) randomized 11,323 post-MI patients to ω-3 PUFA (1 capsule per day providing 850 mg of EPA/DHA in a 1.2:1 ratio; currently available as Lovaza, GlaxoSmithKline, Research Triangle Park, North Carolina) versus usual care (6,17,18). At the end of 1 year of follow-up, patients taking the fish oil supplement had a 15% reduction in the primary end point, including 21% and 30% reductions in total and CV mortality, respectively (Fig. 1). Further analyses showed that this endpoint reduction was driven by a highly significant 45% reduction in SCD, which was evident after only 4 months. In a subgroup analysis from this trial, the magnitude of reduction in total mortality and from SCD increased with progressive worsening of left ventricular (LV) systolic function (17). Long-term follow-up has continued to show reductions in major clinical events at 3.5-year follow-up (18).

Table 1

<table>
<thead>
<tr>
<th>Major Classes of Fatty Acids</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Family</strong></td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>I omega-9</td>
</tr>
<tr>
<td>II omega-6</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>III omega-3</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>IV saturated fats</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*The omega number refers to the position of the first double bond from the methyl end of the molecule. †The notation shows the total number of carbon atoms and total number of double bonds. Adapted with permission from Lavie et al. (2).

DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid.
In another trial, the JELIS (Japan EPA Lipid Intervention Study) trial (7), 18,645 patients (14,981 in primary prevention and 3,664 in secondary prevention) with hypercholesterolemia (70% women) were randomized to statin alone or statin and highly purified EPA 1,800 mg/day. At the end of the 5-year study, those randomized to EPA had a 19% reduction in major CV events (Fig. 2). Unlike the GISSI-Prevenzione study, however, which included lower doses of EPA but also DHA, the moderate dose of EPA alone in the JELIS trial was not associated with a reduction in SCD (possibly because of the virtual absence of SCD in this cohort).

In combination, the DART, GISSI-Prevenzione, and JELIS trials indicated that \(\omega-3\) PUFA lower CV risk in both primary and secondary prevention settings. However, it should be noted that other studies have not shown favorable results. For example, a trial by Burr et al. (19) suggested that patients with angina treated with fish oil capsules seem to have a higher risk of SCD than untreated control subjects. Von Schacky and Harris (20) criticized this trial as being suboptimally conducted or reported, thus the results are questionable. Also, a Norwegian study by Nilsen et al. (21) did not show a benefit of \(\omega-3\) PUFA supplementation in post-MI patients. Why treatment with \(\omega-3\) PUFA was successful in Japan but not in Norway, both populations with a high background intake of \(\omega-3\) PUFA, is not clear, but the much higher number in the former (n = 18,645) versus the latter (n = 300) was likely a factor. Finally, a recent trial (the OMEGA trial) was presented that assessed \(\omega-3\) PUFA (460 mg EPA + 380 mg DHA per day) for 1 year in 3,851 patients 3 to 14 days after acute MI from 104 centers in Germany (22). In these vigorously treated patients (85% to 95% usage of aspirin, clopidogrel, statins, beta-blockers, and angiotensin-converting enzyme inhibitors), the arrhythmic event rate and total mortality were only 0.7% and 3.7%, respectively, in the placebo group, and this trial showed no benefit of EPA/DHA on any of the primary...
or secondary end points. Although this study was probably underpowered to adequately determine the effects of this therapy in secondary CHD prevention, these preliminary results certainly raise the possibility that ω-3 PUFA may not provide additional short-term protection to low-risk patients receiving extensive modern post-MI therapies.

This review does not focus on ALA, which is found in abundance in flaxseed and to a lesser extent in canola and olive oil, walnuts, and other tree nuts, as well as trace amounts in green leafy vegetables. As the only dietary source of ω-3 PUFA, ALA is considered to be inadequate because humans convert typically <5% of ALA to EPA and even less to DHA (23). In some (but not all) epidemiologic studies, ALA has been inversely associated with CV events (3,24). For example, in a recent study from a Costa Rican population, ALA intake and blood levels predicted a better prognosis, independent of fish and EPA/DHA levels, in a post-MI population (25). Nevertheless, the overall evidence is much weaker for ALA than for EPA and DHA.

Evidence in Arrhythmias

We (28) and others (29) have reviewed the antiarrhythmic effects of ω-3 PUFA. Chronic imbalance of the autonomic nervous system, with increases in symptomatic and/or decreases in parasympathetic tone, increases the risk of major CV events and dysrhythmias (3,28). Several randomized controlled trials show that ω-3 PUFA improve sympathovagal balance. Christensen et al. (30) found that patients post-MI and with impaired systolic function had improvements in heart rate variability after 4.3 g/day of EPA and DHA for 12 weeks. Using lower doses of ω-3 PUFA, O’Keefe et al. (31) showed significant reductions in resting heart rate, 1-min heart rate recovery after exercise, and improvement in heart rate variability after 4 months of modest-dose ω-3 PUFA (810 mg/day EPA and DHA). Geelen et al. (32) showed that 14 weeks of moderate-dose ω-3 PUFA (1,260 mg/day EPA and DHA) reduced the average heart rate in patients with complex ventricular arrhythmias. A large study of 5,096 men and women by Mozaffarian et al. (33) showed that high dietary fish intake was associated with lower heart rate, slower atrial ventricular conduction, and a substantially lower likelihood of having a prolonged QT interval. In aggregate, these studies suggest that ω-3 PUFA have benefits in improving autonomic function.

Current research suggests that ω-3 PUFA may prevent fatal arrhythmias via their ability to inhibit fast, voltage-dependent sodium channels and L-type calcium channels (28). Furthermore, DHA has been shown to directly inhibit the delayed-rectifier potassium channel, which is responsible for the depolarization phase of ventricular and atrial cardiac potentials. Although the relative effects of DHA and EPA remain uncertain, DHA’s effect on atrial and ventricular repolarization raises the possibility that DHA could provide greater protection against dysrhythmias, a fact that is supported by the beneficial effects of combined EPA and DHA against SCD in the GISSI-Prevenzione trial (6) but not noted with higher doses of EPA alone in the JELIS trial (7).

Although ω-3 PUFA seem to be effective in reducing SCD in post-MI and in CHD patients with LV dysfunction (6,15–17), 3 trials using ω-3 PUFA in patients with implantable cardioverter-defibrillators (ICDs) have shown mixed results (34–36). The initial trial received substantial negative publicity when a subgroup of ω-3 PUFA–treated patients had more frequent ICD discharges compared with the placebo group, suggesting that these supplements may be proarrhythmic in certain patients (34). In another trial, Leaf et al. (35) found a trend for lower risk for the combined end point of ICD discharge + death from any cause (−28%; p = 0.057) in the group randomized to ω-3 PUFA, with risk reduction of close to 40% (p = 0.03) when adjusting for probable episodes of malignant arrhythmias and compliance. A third trial (and the largest) showed no significant differences between ω-3 PUFA and placebo in patients with ICD, but in a subgroup with prior MI, the ω-3 PUFA group had a trend toward benefit (p = 0.09) (36). These trials used 1.8, 2.6, and 0.8 g of ω-3 PUFA daily, respectively. The GISSI-HIF study, discussed later, did not show any benefits against SCD with the same dose of ω-3 PUFA used in the GISSI-Prevenzione study, raising the possibility that ω-3 PUFA may not benefit SCD risk with large populations with significant LV dysfunction.

Perhaps the most significant antiarrhythmic effects, however, have been noted in studies of AF (28). Mozaffarian et al. (37) showed a 30% lower risk of AF over a 12-year follow-up in patients who consumed high quantities of nonfried fish. However, the Rotterdam study (38) found no
such correlation. Two studies in patients undergoing coronary artery bypass grafting have suggested >50% reductions in the development of post-surgical AF in patients pretreated with ω-3 PUFA with the number needed to treat being only 5.5 in one study (39); one of the studies also showed significant reduction in days hospitalized (39,40). Whether these benefits are caused by antiarrhythmic effects, benefits on autonomic tone, or even anti-inflammatory effects is impossible to determine from these trials. However, these trials point out the potential benefits of ω-3 PUFA in the current epidemic of AF.

Evidence of Benefit in HF

Recently, the potential benefits of ω-3 PUFA have been extended to the prevention and treatment of HF. The Cardiovascular Health Study, involving 4,738 men and women ≥65 years of age, found an inverse association of baked or broiled fish intake and incident congestive HF (Fig. 3) (41). This result was supported by recent data from the ARIC (Atherosclerosis Risk in Community) study, showing an inverse relationship between ω-3 PUFA intake and incident HF in women (42). A recent study by Yamagishi et al. (43) in a prospective study of nearly 60,000 Japanese followed up for nearly 13 years showed an inverse association between fish and ω-3 PUFA consumption and CV mortality, especially for HF. These results are particularly striking in a society with a comparatively high intake of fish and background ω-3 PUFA intake.

Confirmatory evidence was recently presented and published in the GISSI-HF trial (8), a large, factorial, placebo-controlled trial of nearly 7,000 patients with class II to IV HF who were randomized to 1 g of ω-3 PUFA (1 highly concentrated fish oil capsule, Lovaza, containing 850 to 882 mg of EPA + DHA), rosuvastatin (10 mg), both, or dual placebo. This large and well-done study showed a statistically significant benefit of the prescription ω-3 PUFA (Fig. 4), including reduction in total mortality (−9%; p < 0.05) and total mortality or hospitalizations for CV diseases (−8%; p < 0.01). Although these benefits seem to be only modest, they translate into 56 patients needing to be treated for 4 years to avoid 1 death or hospital CV admission. Importantly, this therapy was safe and well tolerated, and the improvements in clinical outcomes were additive to that of other well-established HF therapies, including beta-blockers, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, and aldosterone receptor blockers. Unlike the GISSI-Prevenzione trial (6), which used the same dose of concentrated prescription ω-3 PUFA, prevention of SCD did not seem to explain the benefits of fish oil in HF, nor did HF hospitalizations account for these benefits.
Questions remain regarding the mechanisms responsible for the ω-3 PUFA effects in HF. In addition to the established effects of fish oil therapy, both EPA and DHA are potent activators of peroxisome proliferator-activator receptor (PPAR)-alpha (found in the heart) and PPAR-gamma (44). Although fatty acids are classically viewed as an energy substrate, they are also endogenous ligands for PPARs and regulate the expression of genes encoding key proteins controlling myocardial fatty acid uptake and metabolism (45). Stanley et al. (46) have shown that a high-fat diet increases plasma free fatty acid concentration, activating PPAR-alpha in the heart and stimulating expression of key mitochondrial proteins involving fatty acid oxidation. Duda et al. (47) observed that dietary ω-3 PUFA from fish oil (>1.6 g EPA + DHA) significantly increases serum levels of the cardioprotective adipokine adiponectin in rats subjected to either sham treatment or hypertension induced by abdominal aortic banding. Most importantly, the increase in adiponectin corresponded to significant attenuation of LV hypertrophy and correlated with decreased LV end-systolic volume. Recent evidence suggests that ligand activation of PPAR-gamma by EPA and/or DHA up-regulates adiponectin and suppression of inflammatory cytokines (48–50), which could improve cardiac structure and function in HF (51,52). Thus, important cardiac remodeling effects may underlie the observed clinical benefits of fish oils in HF.

In a small 18-week pilot study of 14 patients with class III to IV HF randomized to 5.1 g/day of EPA and DHA, we showed marked improvements in inflammatory cytokines (e.g., tumor necrosis factor alpha and interleukin-1), and percent body fat in advanced HF, suggesting that fish oil may be beneficial in decreasing inflammation and cachexia in advanced HF (53). This suggests a potentially novel therapeutic approach in the late stages of HF. In addition, our study raises the issue of the dose needed to obtain maximal clinical benefits in patients with HF. Both the GISSI-HF study (8) and the Japan epidemiological study (43) likewise raised the possibility that pharmacological doses may be needed in patients with HF. Animal studies in cardiac remodeling suggest the need for higher doses as well. Therefore, further studies are needed determining not only the optimal dose of ω-3 PUFA protection in different stages of HF but also the underlying mechanisms accountable for their benefits. However, at present, we agree with Fonarow’s (54) assertion that ω-3 PUFA supplementation “should join the short list of evidence-based lifetime-prolonging therapy for HF.”

Evidence for Benefit in Hyperlipidemia

The U.S. Food and Drug Administration (FDA) has approved an ω-3 PUFA ethyl ester formulation (Lovaza), at a dosage of 4 g/day for the treatment of very high triglyceride levels (≥500 mg/dl) (55–57). It is well established that ω-3 PUFA lower plasma triglyceride concentrations (20,58,59). The mechanism for these lipid-lowering effects seems to involve activation of PPARs. Although fatty acids are classically observed as an energy substrate, they are also endogenous ligands for PPARs and regulate the expression of genes encoding key proteins controlling fatty acid uptake and metabolism and the formation of very-low-density lipoproteins carrying triglycerides in the liver (60,61). Although the exact transcriptional mechanism by which fish oils improve lipid levels is not completely understood, ω-3 PUFA do reduce hepatic synthesis of triglycerides and increase hepatic fatty acid beta-oxidation. The triglyceride-lowering doses of DHA and EPA is 3 to 4 g/day. This dose typically reduces triglyceride levels by 30% to 40% (59) and has been shown to reduce severely elevated triglyceride levels (>500 mg/dl) by 45%, along with reductions in non-high-density lipoprotein cholesterol by 14% with a 9% increase in high-density lipoprotein cholesterol (62). Generally, there are no significant improvements in levels of low-density lipoprotein (LDL) cholesterol with fish oil therapy, especially in patients with elevated triglyceride levels, who often notice increases between 5% and 50% (depending on the severity of the hypertriglyceridemia and baseline LDL levels) (62). Interestingly, in the JELIS study, moderate doses of EPA resulted in 10% reductions in LDL cholesterol beyond that produced by low-dose statins (7). Nevertheless, even when LDL cholesterol increases with ω-3 PUFA, as it can with fibrates and occasionally with niacin, ω-3 PUFA–enriched LDL has been reported to be larger and fluffier (pattern A), which is potentially less atherogenic than the smaller, denser (pattern B) LDL particles (64). Although typically more expensive than dietary supplements, the capsular form is a standardized prescription preparation (Lovaza, 4 g) with FDA-approved safety and efficacy data and is the most concentrated source of DHA and EPA available.

Additional Mechanisms and Optimal DHA/EPA Ratios

A detailed discussion of all of the potential mechanisms of ω-3 PUFA and CV diseases (summarized in Table 2) is beyond the scope of this review. It appears that ω-3 PUFA confer CV benefits largely through DHA and EPA enrichment of membrane phospholipids (65). In addition to mechanisms discussed above, ω-3 PUFA produces vasodilation, reduces blood pressure (31,66), improves arterial and endothelial function (67), and reduces platelet aggregation (68). The antiplatelet, anti-inflammatory, and triglyceride-lowering effects of ω-3 PUFA (Fig. 5) (69) require relatively higher doses of DHA and EPA (e.g., 3 to 4 g/day), whereas some of the antiarrhythmic effects, reduction of SCD, and improvement in HF can be achieved at lower doses (500 to 1,000 mg/day). Nevertheless, higher doses may be even more effective in HF, as discussed previously. Although the effects of ω-3 PUFA on C-reactive protein levels have been inconsistent (70), these agents have been.

590 Lavie et al.
Omega-3 PUFA and CV Diseases

shown to suppress production of pro-inflammatory cytokines such as interleukin-1B, interleukin-6, and tumor necrosis factor-alpha (71). When administered to obese patients, 1.8 g of EPA increased the levels of adiponectin, which can reduce inflammation and improve insulin sensitivity (72), in addition to the potential beneficial HF effects discussed earlier. Although benefits on the autonomic nervous system are well established and are reviewed earlier, studies in patients undergoing heart transplantation suggest that ω-3 PUFA can reduce heart rate independently of vagal activation (73), in addition to reducing mean arterial pressure and systemic vascular resistance by 25% and reducing LV hypertrophy and improving diastolic function in heart transplantation patients with cyclosporine-induced hypertension (66).

The optimal doses and ratios of DHA to EPA are difficult to decipher. Both DHA and EPA are present in most fish, particularly oily ones, generally in a 2:1 ratio (Table 3) (3,74), whereas fish oils typically have a ratio of 2:3 or lower (3). Although feeding pure DHA can raise EPA levels to a small extent (75), the reverse is not true (76). Additionally, DHA is far more abundant than EPA in the myocardium (68). As reviewed earlier, DHA alone or in combination with EPA may be more important for protection against dysrhythmias and SCD than EPA alone. Although the beneficial effects on dysrhythmias seem to occur at lower doses, the relative risk of SCD has been shown to be related with baseline blood levels of ω-3 PUFA (Fig. 6) (3,77) and, as reviewed earlier, protection against CHD was also inversely related with tissue levels of EPA and, more so, with DHA levels (15). In addition, other surrogate CV markers (arterial pressure, endothelial relaxation and attenuated vascular relaxation, and lipoproteins) may be more improved with high doses of DHA than with similar doses of EPA (78).

<table>
<thead>
<tr>
<th>Fish Content of EPA and DHA</th>
<th>Type</th>
<th>DHA (g/100 g)</th>
<th>EPA (g/100 g)</th>
<th>DHA and EPA (g/100 g)</th>
<th>Ratio</th>
<th>DHA/EPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuna</td>
<td>Bluefin</td>
<td>1.141</td>
<td>0.363</td>
<td>1.504</td>
<td>3.1:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Light, canned in water</td>
<td>0.223</td>
<td>0.047</td>
<td>0.270</td>
<td>4.8:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Albacore, canned in water</td>
<td>0.629</td>
<td>0.233</td>
<td>0.862</td>
<td>2.7:1.0</td>
<td></td>
</tr>
<tr>
<td>Salmon</td>
<td>Atlantic, farmed</td>
<td>1.457</td>
<td>0.690</td>
<td>2.147</td>
<td>2.1:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atlantic, wild</td>
<td>1.429</td>
<td>0.411</td>
<td>1.840</td>
<td>3.5:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chinook</td>
<td>0.727</td>
<td>1.010</td>
<td>1.737</td>
<td>1.0:1.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sockeye</td>
<td>0.700</td>
<td>0.530</td>
<td>1.230</td>
<td>1.3:1.0</td>
<td></td>
</tr>
<tr>
<td>Mackerel, Atlantic</td>
<td>0.699</td>
<td>0.504</td>
<td>1.203</td>
<td>1.4:1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herring, Atlantic</td>
<td>1.105</td>
<td>0.909</td>
<td>2.014</td>
<td>1.2:1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trout</td>
<td>Rainbow, farmed</td>
<td>0.820</td>
<td>0.334</td>
<td>1.154</td>
<td>2.5:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rainbow, wild</td>
<td>0.520</td>
<td>0.468</td>
<td>0.988</td>
<td>1.1:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Halibut</td>
<td>0.374</td>
<td>0.091</td>
<td>0.465</td>
<td>4.1:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cod</td>
<td>0.154</td>
<td>0.004</td>
<td>0.158</td>
<td>38.5:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Haddock</td>
<td>0.162</td>
<td>0.076</td>
<td>0.238</td>
<td>2.1:1.0</td>
<td></td>
</tr>
<tr>
<td>Catfish</td>
<td>Channel, farmed</td>
<td>0.128</td>
<td>0.049</td>
<td>0.177</td>
<td>2.6:1.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Channel, wild</td>
<td>0.137</td>
<td>0.100</td>
<td>0.237</td>
<td>1.4:1.0</td>
<td></td>
</tr>
<tr>
<td>Swordfish</td>
<td>0.681</td>
<td>0.087</td>
<td>0.768</td>
<td>7.8:1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grouper</td>
<td>0.213</td>
<td>0.035</td>
<td>0.248</td>
<td>6.1:1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shrimp</td>
<td>0.144</td>
<td>0.171</td>
<td>0.315</td>
<td>2.1:1.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data from the USDA Agricultural Research Service (74) and reprinted, with permission, from Lee et al. (3).

Abbreviations as in Table 1.
Safety and Adverse Effects

The most commonly observed adverse effects of ω-3 PUFA supplementation are nausea, gastrointestinal upset, and “fishy” burp. Prolonged bleeding times, as noted in Greenland Eskimos and when feeding “hyper-Eskimo” doses of ω-3 PUFA (e.g., over 20 g/day) to normal volunteers, usually remain in the high end of the normal range (3,10). These observations, however, raised concerns that higher intakes will increase hemorrhagic complications. However, Harris (79), in a comprehensive review, concluded that there was no increased risk of clinically significant bleeding noted with ω-3 PUFA doses of up to 7 g of combined DHA and EPA per day, even when combined with antiplatelet therapy or warfarin.

One of the major concerns, not about EPA and DHA per se, but about diets high in oily fish, is the consumption of contaminants, namely methyl mercury. For this reason, the FDA has advised children and pregnant or nursing women to specifically avoid those fish with a potentially high content of mercury, such as swordfish, tile fish, king mackerel, and shark (80). Nevertheless, a study of nearly 12,000 British women during their pregnancy and beyond found that women who exceeded the U.S. FDA recommendation for fish intake actually had offspring with better cognitive and behavioral development than offspring of women who consumed less fish during pregnancy (81). A large meta-analysis by Mozafarian and Rimm (82) also showed the favorable risk-to-benefit ratio (1:400) associated with a high consumption of fish. Importantly, the most commonly consumed dietary sources of ω-3 PUFA, such as salmon, sardines, trout, oysters, and herring, are quite low in mercury (3). Because mercury is water soluble and protein bound, it is present in the muscle of the fish but not in the oil. Therefore, fish oil supplements should contain negligible amounts of mercury (83).

Conclusions

Convincing evidence from extensive research over the past 3 decades points out the potential beneficial effects of ω-3 PUFA in primary prevention, CHD and post-MI, SCD, HF, atherosclerosis, and AF. Based on the growing evidence for the benefits of fish oils, we agree that this story represents a “fish tale with growing credibility.” We also agree with Rogans’ comment from over 20 years ago that “fish oil is a whale of a story, that not surprisingly gets bigger with every telling” (1).

Acknowledgment

The authors thank Dr. William S. Harris for helpful advice during early drafts of this review.
REFERENCES

22. Senges S, for the OMEGA Study Group. Randomized trial of omega-3 fatty acids on top of modern therapy after acute myocardial infarction: the OMEGA trial. Oral presentation at: Annual Scientific Sessions of the American College of Cardiology, March 2009; Orlando, FL.
**Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases**
Carl J. Lavie, Richard V. Milani, Mandep R. Mehra, and Hector O. Ventura

*J. Am. Coll. Cardiol.* 2009;54;585-594
doi:10.1016/j.jacc.2009.02.084

**This information is current as of August 6, 2009**

<table>
<thead>
<tr>
<th>Updated Information</th>
<th>including high-resolution figures, can be found at:</th>
</tr>
</thead>
<tbody>
<tr>
<td>&amp; Services</td>
<td><a href="http://content.onlinejacc.org/cgi/content/full/54/7/585">http://content.onlinejacc.org/cgi/content/full/54/7/585</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 82 articles, 39 of which you can access for free at:</td>
</tr>
<tr>
<td></td>
<td><a href="http://content.onlinejacc.org/cgi/content/full/54/7/585#BIBL">http://content.onlinejacc.org/cgi/content/full/54/7/585#BIBL</a></td>
</tr>
<tr>
<td>Rights &amp; Permissions</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:</td>
</tr>
<tr>
<td></td>
<td><a href="http://content.onlinejacc.org/misc/permissions.dtl">http://content.onlinejacc.org/misc/permissions.dtl</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online:</td>
</tr>
<tr>
<td></td>
<td><a href="http://content.onlinejacc.org/misc/reprints.dtl">http://content.onlinejacc.org/misc/reprints.dtl</a></td>
</tr>
</tbody>
</table>